DRMA

Mary Fisher

Known title: DirectorCIK: 0001272360

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 15, 2026

Dermata Reports Positive Results from Tome Cosmetic Study. Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.

this person other insiders at DRMA

Transaction History

DRMA▲ Buy—
DRMA▲ Buy$0
DRMA▲ Buy$0
DRMA▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.